Market Overview

Analysts Call Verrica A Buy For Vast Molluscum Opportunity

Analysts Call Verrica A Buy For Vast Molluscum Opportunity

Investors who bought into Verrica Pharmaceuticals Inc (NASDAQ: VRCA) at its June 15 IPO are celebrating 13.1-percent returns.

The gains should continue, in the view of two new sell-side bulls.

The Ratings

Bank of America Merrill Lynch analyst Jason Gerberry initiated coverage of Verrica with a Buy rating and $26 price target.

Cowen analyst Ken Cacciatore initiated coverage with an Outperform rating and $35 target.

The Theses

The analysts are bullish on Verrica for its lead candidate, VP-102, which is in Phase 3 trials for the treatment of molluscum.

The therapy — a non-invasive alternative to cryotherapy and surgery — is poised to become the first approved molluscum drug for a potentially underdiagnosed population growing by an estimated 1 million U.S. patents per year.

Bank of America expects dermatologists to be receptive to VP-102 considering the drug’s familiar active ingredient.

“Supportive Phase 2 data suggests VP-102 can achieve high clearance rates, which have made the API popular with dermatologists,” Gerberry said in a Tuesday note. (See the analyst's track record here.)

BofA forecast a 60-percent possibility of success and anticipates favorable Phase 3 data will boost the likelihood to 85 percent. Cowen's Cacciatore expressed similar optimism.

"With what we believe will be a very reasonable pricing strategy that should secure broad coverage, combined with FDA guidelines that mandate the discontinuation of compounded versions of approved products — as well as what appears to be limited raw material supplies — we believe that Verrica’s formulation will quickly capture, penetrate, and expand the current treatment market," the analyst said in a Tuesday note. (See Cacciatore's track record here.)

Indication expansion into common warts could drive additional upside for Verrica.

Price Action

Verrica shares were down 6.22 percent at $18.54 at the close Tuesday.

Related Links:

After Biogen's Alzheimer's Update, Wall Street Reacts

Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

Latest Ratings for VRCA

Feb 2019Initiates Coverage OnBuy
Jul 2018Initiates Coverage OnBuy
Jul 2018Initiates Coverage OnOutperform

View More Analyst Ratings for VRCA
View the Latest Analyst Ratings

Posted-In: Analyst Color Health Care Price Target Initiation Top Stories Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (VRCA)

View Comments and Join the Discussion!

Latest Ratings

HRIGoldman SachsUpgrades60.0
ERICDZ BankUpgrades
RUTHPiper JaffrayMaintains22.0
DRIPiper JaffrayReiterates128.0
SWKSBenchmarkInitiates Coverage On94.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

There's An App For That: Apple's App Store Celebrates 10th Anniversary

Mixed Drinks: Combined Keurig Dr Pepper Debuts On NYSE